Factor | HR (95% CI) | p value |
---|---|---|
Type of bDMARD | ||
 TNFi(mAb)/TNFi(R/P) | 0.67 (0.42–1.08) | 0.10 |
 TNFi(mAb)/CTLA4-Ig | 1.04 (0.54–1.97) | 0.91 |
 TNFi(mAb)/IL-6Ri | 0.63 (0.40–0.99) | 0.05 |
 CTLA4-Ig/TNFi(R/P) | 0.65 (0.33–1.29) | 0.22 |
 CTLA4-Ig/IL-6Ri | 0.61 (0.31–1.18) | 0.14 |
 TNFi(R/P)/IL-6Ri | 0.93 (0.56–1.56) | 0.79 |
Disease duration < 2 years /≥ 2 years | 0.97 (0.65–1.44) | 0.89 |
bDMARD-naïve, naïve/switch | 0.85 (0.57–1.26) | 0.42 |
Reason for discontinuation, remission/other reason | 0.66 (0.38–1.14) | 0.13 |
Boolean remission at the time of discontinuation, achieved/not achieved | 0.63 (0.42–0.93) | 0.02 |
Remission maintenance period before discontinuation, > 6 months/≥ 6 months | 0.50 (0.32–0.78) | 0.00 |
Methotrexate usage at the time of discontinuation, yes/no | 1.10 (0.70–1.74) | 0.67 |
Glucocorticoid usage at the time of discontinuation, yes/no | 1.50 (1.05–2.15) | 0.03 |